首页> 外国专利> LIPOCALIN MUTEINS WITH BINDING-AFFINITY FOR GLYPICAN-3 (GPC-3) AND USE OF LIPOCALIN MUTEINS FOR TARGET-SPECIFIC DELIVERY TO CELLS EXPRESSING GPC-3

LIPOCALIN MUTEINS WITH BINDING-AFFINITY FOR GLYPICAN-3 (GPC-3) AND USE OF LIPOCALIN MUTEINS FOR TARGET-SPECIFIC DELIVERY TO CELLS EXPRESSING GPC-3

机译:具有结合能力的Glypican-3(GPC-3)脂蛋白卡林突变蛋白和脂蛋白卡林蛋白突变蛋白在表达GPC-3的细胞中的靶向传递作用。

摘要

The present invention relates to novel, specific-binding therapeutic and/or diagnostic lipocalin muteins directed against Glypican-3 (GPC-3). The invention also relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the invention also is directed to pharmaceutical compositions comprising such muteins and practical uses of these lipocalin muteins. In addition, the present invention provides methods of using muteins of human lipocalin 2 (Lcn2 or NGAL) for target-specific delivery of therapeutic moieties or detectable labels to cells expressing GPC-3, and related therapeutic and diagnostic utilization.
机译:本发明涉及针对Glypican-3(GPC-3)的新颖的,特异性结合的治疗和/或诊断性脂钙蛋白突变蛋白。本发明还涉及编码此类突变蛋白的核酸分子以及产生此类突变蛋白和核酸分子的方法。另外,本发明还涉及包含此类突变蛋白的药物组合物以及这些脂环蛋白突变蛋白的实际用途。另外,本发明提供了使用人脂质运载蛋白2(Lcn2或NGAL)的突变蛋白将治疗部分或可检测标记物特异性地递送至表达GPC-3的细胞的方法,以及相关的治疗和诊断用途。

著录项

  • 公开/公告号US2017066807A1

    专利类型

  • 公开/公告日2017-03-09

    原文格式PDF

  • 申请/专利权人 PIERIS PHARMACEUTICALS GMBH;

    申请/专利号US201615341793

  • 发明设计人 SHANE OLWILL;LAURENT AUDOLY;

    申请日2016-11-02

  • 分类号C07K14/47;A61K47/48;A61K51/08;

  • 国家 US

  • 入库时间 2022-08-21 13:47:03

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号